Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see what dose of 225Ac-lintuzumab is safest to give to acute
myeloid leukemia (AML) patients who are in remission but still have minimal residual disease
(MRD). About 12 subjects will be asked to take part in this phase 1, 3+3 dose-escalation
study. In addition to confirming the safety profile of postremission therapy with
225Ac-lintuzumab, preliminary evidence of efficacy will be assessed by estimating
progression-free survival (PFS) and overall survival (OS), and serially evaluating for MRD
using cytogenetics, fluorescence in situ hybridization (FISH), or flow cytometric assays, as
applicable.